{"created":"2021-12-03T01:40:50.476288+00:00","id":2001659,"links":{},"metadata":{"_buckets":{"deposit":"21527e97-10d5-44b8-a817-49bf56b756d9"},"_deposit":{"created_by":17,"id":"2001659","owners":[17],"pid":{"revision_id":0,"type":"depid","value":"2001659"},"status":"published"},"_oai":{"id":"oai:nagoya.repo.nii.ac.jp:02001659","sets":["499:508:509:1638493189962"]},"author_link":[],"item_1615768549627":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_9_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-11","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"4","bibliographicPageEnd":"785","bibliographicPageStart":"773","bibliographicVolumeNumber":"83","bibliographic_titles":[{"bibliographic_title":"Nagoya Journal of Medical Science","bibliographic_titleLang":"en"}]}]},"item_9_description_4":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"Carboplatin (CBDCA)-induced emetic risk is currently classified on the basis of CBDCA-area under the curve (CBDCA-AUC). We investigated the utility of three CBDCA dosage parameters for predicting emesis by CBDCA. Patients with thoracic cancer treated with CBDCA were included. The endpoints were complete response (CR) and total control (TC). CR was defined as no vomiting and no use of rescue medication during the overall assessment period, whereas TC was defined as no vomiting, nausea, nor use of rescue medication during the overall assessment period. The parameters of CBDCA were defined as follows: (1) CBDCA-AUC; (2) CBDCA/body surface area (BSA): the administered dose of CBDCA per body surface area (mg/m2); and (3) total CBDCA/body: the total administered dose of CBDCA (mg). Eighty-five patients were evaluated. The median CBDCA/BSA but not CBDCA-AUC was higher in patients with non-CR compared to those with CR. Receiver operating characteristic curve analysis revealed that the AUC of CBDCA/BSA for predicting non-CR was higher than that of CBDCA-AUC. CBDCA/BSA shows greater potential for predicting CBDCA-induced emetic risk compared with CBDCA-AUC, which is the parameter in current antiemetic guidelines.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_9_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.18999/nagjms.83.4.773","subitem_identifier_reg_type":"JaLC"}]},"item_9_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Nagoya University Graduate School of Medicine, School of Medicine","subitem_publisher_language":"en"}]},"item_9_relation_43":{"attribute_name":"関連情報","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/834.html","subitem_relation_type_select":"URI"}}]},"item_9_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International","subitem_rights_language":"en","subitem_rights_resource":"http://creativecommons.org/licenses/by-nc-nd/4.0/"}]},"item_9_source_id_7":{"attribute_name":"収録物識別子","attribute_value_mlt":[{"subitem_source_identifier":"0027-7622","subitem_source_identifier_type":"PISSN"},{"subitem_source_identifier":"2186-3326","subitem_source_identifier_type":"EISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Ozone, Sachiko","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Ichikawa, Kazuya","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Morise, Masahiro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Matsui, Akira","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kinoshita, Fumie","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Matsuzawa, Reiko","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Koyama, Junji","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Tanaka, Ichidai","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Hashimoto, Naozumi","creatorNameLang":"en"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2021-12-03"}],"displaytype":"detail","filename":"12_Ozone.pdf","filesize":[{"value":"578 KB"}],"format":"application/pdf","licensetype":"license_5","mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://nagoya.repo.nii.ac.jp/record/2001659/files/12_Ozone.pdf"},"version_id":"9ed681fa-69c5-4152-b71f-41409d346357"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"carboplatin","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"chemotherapy-induced nausea and vomiting (CINV)","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"moderate emetic risk regimen","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"antiemetic treatment","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"antiemetic guideline recommendations","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Is area under the curve the best parameter for carboplatin induced emetic risk stratification?","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Is area under the curve the best parameter for carboplatin induced emetic risk stratification?","subitem_title_language":"en"}]},"item_type_id":"40001","owner":"17","path":["1638493189962"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2021-12-03"},"publish_date":"2021-12-03","publish_status":"0","recid":"2001659","relation_version_is_last":true,"title":["Is area under the curve the best parameter for carboplatin induced emetic risk stratification?"],"weko_creator_id":"17","weko_shared_id":-1},"updated":"2023-11-16T01:56:33.445464+00:00"}